Simplifying Global Compliance
Janssen’s SGLT-2 Diabetes Drug Gets Tentative Thumbs Up From FDA Panel
Washington Drug Letter
A panel of FDA advisers voted to recommend approval of Janssen Pharmaceuticals’ Type 2 diabetes drug canagliflozin, saying the drug’s apparent cardiovascular risks (CV) were likely a product of incomplete safety data and could be allayed by long-term postmarket studies.
To View This Article:
Buy This Article Now
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing